Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
CLOV vs WTW: Weighing High-Growth Medicare Momentum Against Steady Advisory Stability

CLOV vs WTW: Weighing High-Growth Medicare Momentum Against Steady Advisory Stability

Key Takeaways

  • CLOV is a fast-growing Medicare Advantage and physician-enablement technology company, while WTW is a diversified global advisory, broking, and solutions firm with steadier, more mature economics.
  • Recent momentum clearly favors CLOV: it is riding rapid membership growth, a top-quality plan rating, and a shift toward GAAP profitability, whereas WTW has lagged the broader market in 2026.
  • Risk profiles differ sharply: CLOV carries a high beta and considerable volatility, while WTW offers lower volatility, a dividend, and stronger free cash flow.
  • Relative positioning suggests CLOV is a momentum-and-growth story and WTW is a margin-expansion and efficiency story driven by its "Propel" AI initiative.
  • Tickeron AI Verdict: CLOV — based on trend consistency, catalysts, and relative positioning, Tickeron's AI currently favors CLOV over WTW.
  • For deeper context, explore CLOV Major News, CLOV Today's Price Move, WTW Major News, and WTW Today's Price Move.
  • To see which strategies AI-driven systems are deploying across the market right now, explore Trending AI Robots.

Introduction: Two Distinct Business Models

Comparing CLOV and WTW puts two very different businesses side by side. Clover Health Investments, Corp. is a physician-enablement technology company focused on Medicare Advantage plans, a segment that has delivered explosive top-line growth but historically thin or negative profitability. Willis Towers Watson is a global advisory, broking, and solutions powerhouse that generates consistent earnings and free cash flow across more than 140 countries. This stock comparison is most relevant to investors deciding between a high-growth, higher-volatility healthcare name and a diversified, capital-returning franchise — and to traders weighing momentum and catalysts against stability and income. I also checked sector peers using Tickeron’s AI Screener to put the relative profiles in context.

CLOV Overview and Recent Performance

Clover Health Investments, Corp. operates Medicare Advantage plans and licenses its Clover Assistant software, a clinical decision-support platform for physicians. The company has reported accelerating momentum in recent quarters: first-quarter 2026 revenue rose roughly 62% year over year to about $749 million, while Medicare Advantage membership climbed more than 50% to approximately 155,000 members. Adjusted EBITDA reached about $40 million, and the company generated positive operating cash flow.

Recent market activity has been supported by several catalysts. The Centers for Medicare & Medicaid Services awarded Clover's PPO plans a five-star rating for 2027, a quality milestone that can strengthen benefit competitiveness and future enrollment. Analysts have responded favorably, with several firms initiating or maintaining Buy ratings in recent weeks. The stock has been notably volatile — its beta is well above the market average — but has outperformed its industry year to date, reflecting investor enthusiasm for the company's path toward full-year GAAP net income profitability in 2026.

WTW Overview and Recent Performance

Willis Towers Watson operates two primary segments: Risk & Broking, which provides insurance brokerage and advisory services, and Health, Wealth & Career, which delivers benefits, retirement, and compensation consulting. In its most recent quarter, WTW reported revenue of roughly $2.46 billion, up 8% year over year, with organic growth of about 4% and adjusted diluted EPS up 18%.

WTW's narrative in recent weeks has centered on "Propel," an AI acceleration plan approved in mid-2026. The company is investing approximately $625 million through 2028, targeting roughly $350 million in net run-rate savings and a 30% adjusted operating margin. Management has also completed the integration of the Newfront acquisition, which closed in early 2026. Despite solid operational execution, the stock has modestly underperformed the broader market in 2026, and consensus estimate revisions have been mixed. WTW continues to return capital through dividends and share repurchases, reinforcing its profile as a stable, cash-generative franchise.

Head-to-Head Comparison

The two companies diverge across nearly every fundamental dimension. CLOV is a concentrated, technology-enabled healthcare operator whose growth depends on Medicare Advantage enrollment, quality ratings, and medical-cost management. Its revenue base is scaling rapidly, but profitability is still emerging and its earnings stream remains less predictable. WTW is a diversified, fee-based advisory business with high retention, steady margins, and substantial free cash flow, but its growth is slower and more cyclical through corporate spending and insurance pricing.

From a risk standpoint, CLOV's elevated beta reflects higher sensitivity to market swings and to policy changes affecting Medicare. WTW's risk is more operational, tied to acquisition integration, restructuring costs, and the execution of its AI-driven margin plan. Sentiment also contrasts: CLOV has attracted positive analyst initiations and a quality-rating catalyst, while WTW has faced mixed estimate revisions and lagged the market in 2026. In terms of market positioning, CLOV offers a higher-upside, higher-volatility growth profile, whereas WTW offers lower-volatility income and efficiency-driven margin expansion.

Tickeron AI Verdict

Based on observable factors such as trend consistency, momentum, catalyst density, and relative positioning, Tickeron's AI currently favors CLOV over WTW. CLOV's combination of rapid membership growth, a five-star quality rating, improving cash generation, and a shift toward GAAP profitability presents a clearer near-term catalyst path. By contrast, WTW's efficiency program and margin targets are weighted toward 2027 and 2028, and its shares have shown weaker relative momentum. The assessment is probabilistic rather than definitive: CLOV's higher volatility and still-emerging profitability carry meaningful risk, and WTW's stability and cash flow remain attractive to a different investor profile. The AI verdict reflects current trend and catalyst alignment rather than a guarantee of future performance. I also reviewed trend data with Tickeron’s AI Trend Prediction Engine to confirm the directional signals.

Exploring AI-Driven Strategies

One resource I return to regularly is Tickeron’s Trending AI Robots. It highlights automated systems currently performing well across different timeframes and risk levels, giving a practical way to compare verified historical statistics without building custom models from scratch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WTW, CLOV

WTW in upward trend: 10-day moving average crossed above 50-day moving average on October 26, 2026

The 10-day moving average for WTW crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on WTW as a result. In 58 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.

WTW moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where WTW advanced for three days, in 145 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 47%.

The Aroon Indicator entered an Uptrend today. In 155 of 270 cases where WTW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.

Bearish Trend Analysis

The 10-day RSI Indicator for WTW moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 17 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 69 cases where WTW's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.

The Moving Average Convergence Divergence Histogram (MACD) for WTW turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 17 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 35%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WTW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

WTW broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. WTW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 47 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.973) is normal, around the industry mean (2.794). P/E Ratio (20.287) is within average values for comparable stocks, (19.877). Projected Growth (PEG Ratio) (1.265) is also within normal values, averaging (8.322). Dividend Yield (0.012) settles around the average of (0.042) among similar stocks. P/S Ratio (2.990) is also within normal values, averaging (3.106).

Notable companies

The most notable companies in this group are eHealth (NASDAQ:EHTH).

Industry description

Insurance brokers sell, solicit, or negotiate insurance for compensation. General insurance brokers mostly cater to insurances on car, house etc. (versus life). Brokers are also often instrumental in helping small employers find health insurance, particularly in more competitive markets. Additionally, brokers may also provide risk assessments, insurance consulting services, insurance-related regulatory and legislative update services. Some of the major names in this industry include Marsh & McLennan Companies, Inc., Aon plc and Verisk Analytics Inc.

Market Cap

The average market capitalization across the Insurance Brokers/Services Industry is 16B. The market cap for tickers in the group ranges from 3.03K to 97.74B. MRSH holds the highest valuation in this group at 97.74B. The lowest valued company is CUII at 3.03K.

High and low price notable news

The average weekly price growth across all stocks in the Insurance Brokers/Services Industry was -9%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 17%. CRVL experienced the highest price growth at 3%, while ZBAO experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Insurance Brokers/Services Industry was -73%. For the same stocks of the Industry, the average monthly volume growth was 7% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 74
Price Growth Rating: 51
SMR Rating: 70
Profit Risk Rating: 84
Seasonality Score: 8 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of weight management services

Industry InsuranceBrokersServices

Industry
Other Consumer Services
Address
c/o Willis Group Limited
Phone
+44 2031246000
Employees
47000
Web
https://www.willistowerswatson.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.